BioCentury | Nov 24, 2014
Clinical News

2MD: Phase IIb data

...Phase IIb trial in 62 CKD patients receiving hemodialysis showed that thrice-weekly 220-770 ng oral DP001...
...PTH levels vs. a 31% increase for placebo. Deltanoid said that >80% of patients receiving DP001...
...Society of Nephrology meeting in Philadelphia. Deltanoid Pharmaceuticals Inc. , Madison, Wis. Product: 2MD , DP001...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...markets Bonalfa tacalcitol monohydrate, activated vitamin D3, to treat psoriasis. Deltanoid Pharmaceuticals Inc. has DP001 (2MD...
BioCentury | Mar 19, 2007
Clinical News

DP001: Phase II started

...Phase II trial in postmenopausal women. Deltanoid Pharmaceuticals Inc. , Madison, Wis. Product: DP001 , 2MD...
BioCentury | Jan 20, 2003
Product Development

Deltanoid: Curiously strong

...make it a player in the space. The company has preclinical data showing that its 2MD...
...stimulates bone formation in addition to preventing bone loss. Pfizer Inc. took an option on 2MD...
...2MD at concentrations as low as 10-12M caused primary cultures of osteoblasts to produce bone. 2MD...
BioCentury | Jan 20, 2003
Company News

Deltanoid, Pfizer deal

...Deltanoid granted PFE an option to acquire development and marketing rights to its 2MD , an...
...and milestone payments for 2MD, in addition to royalties. In preclinical studies, Deltanoid said that 2MD...
BioCentury | Oct 7, 2002
Company News

Deltanoid Inc. other research news

...Researchers published in the Proceedings of the National Academy of Sciences that 2MD at concentrations as...
...concentrations as low as 10 -12 M caused primary cultures of osteoblasts to produce bone. 2MD...
...a 23-week period compared to control (p<0.001). Deltanoid Inc. , Madison, Wis., et al. Product: 2MD...
Items per page:
1 - 6 of 6